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ABSTRACT 
Background: 
The reasons for lack of seroprotection after Oral Polio Vaccination (OPV) are poorly 
understood. This study explored socio-demographic, nutritional, birth related, water, 
sanitation and operational factors to explain lack of seroprotection to type 3 
poliovirus, in children 6 - 12 months. 
Methods  
The study was conducted in Vellore district in rural and urban low income 
neighbourhoods. This was a case-control study in 142 OPV Type 3 seropositive and 142 
seronegative children who had received OPV, selected at random from an existing cohort 
of children as part of an earlier vaccine study. Data Collection took place between April 
and May 2015. A questionnaire was administered along with measuring height and 
weight. Vaccine status was recorded based on vaccination cards where available (83%) 
and verbal reports from mothers. Univariable and multivariable analysis using logistic 
regression was done.   
Results 
The results suggest that some of the explored biological factors, such as feeding 
colostrums (O.R.:11.77, 95% CI:1.21 – 114.89) and some evidence of early weaning to be 
associated with vaccine failure.  Further, there were trends towards several socio-
economic factors such maternal education (O.R.:0.92, 95% C.I.: 0.86 – 0.99), HAZ score 
(O.R.:0.82, 95% C.I.:0.65 – 1.04) and being able to name the village health nurse 
(possibly a proxy for social inclusion and/or education) being associated with vaccine 
failure (O.R.:1.70, 95% C.I.: 1.00 – 2.88).  The per dose vaccine efficacy was calculated 
to be 26% (7% - 41%). 
Conclusion 
We identified modifiable risk factors such as early weaning and feeding colostrum. 
Exclusive breastfeeding should be encouraged as the overall benefit of feeding colostrum 
with respect to the risk of diarrhea and pneumonia is likely to exceed the risks associated 
with non-seroconversion to OPV. Other risk factors identified in this study are related to 
more upstream socio-economic and educational factors tackling of which will require 
broad political and social measures.  
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1 INTRODUCTION 
Lack of seroconversion following oral polio vaccine is well documented in low 
income settings across the globe including South Asia. Children living in low 
income countries and in low income settings within middle income countries have 
shown to have a lower immune response to oral vaccines as opposed to children 
from high income settings (1, 2). 
Oral poliovirus vaccine (OPV) continues to be the preferred agent over injectable 
inactivated poliovirus vaccine (IPV) for eradication as the live vaccine produces a 
local immune response in the mucosal lining of the intestine (the primary site of 
replication). This in turn prevents the replication and excretion of the virus and 
places a barrier for its transmission (3).  Other reasons include that it is cheap and 
easier to administer at a larger scale. 
Low and middle income countries, including India, are in the process of moving 
from OPV to IPV. However, until IPV vaccine coverage is  greater than 85%, the 
risk of circulating vaccine-derived polioviruses is high (4). Therefore, OPV 
continues to be in great demand to prevent this risk till coverage with IPV is 
adequate. OPV is a crucial part in the end game to the eradication of polio. In this 
context, the poor response to OPV in low income settings continues to be of high 
public health relevance. 
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Many factors have been implicated in its poor immune response, which are yet to 
be fully understood.  With the changing demographics and nutritional transition in 
low income settings, the need to study these factors is crucial in understanding the 
best way of using OPV to assist in the eradication of polio. 
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2.  JUSTIFICATION 
While several biological and non-biological factors have been implicated in children 
with vaccine failure, the underlying epidemiological determinants of poor immune 
response to OPV and other oral vaccines, including cholera and rotavirus, have not 
been fully understood. In particular, there is a paucity of evidence for the role of 
socio-demographic, nutritional, gender and operational factors in seroprotection (5).  
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3.  OBJECTIVES 
Overall Aim: 
To explore risk factors for lack of seroprotection to type 3 oral poliovirus in 
children between 6 and 12 months of age in rural South India 
Specific objectives 
1) To assess the effect of socio-demographic, and socio-economic risk 
factors such as level of education, socio-economic status, water, sanitation 
and distance to the health clinic on lack of seroprotection to type 3 
poliovirus in children between 6 and 12 months. 
 
2) To assess the effect of biological risk factors such as nutritional status, 
early weaning, feeding colostrum and concurrent illnesses on lack of 
seroprotection to type 3 poliovirus in children between 6 and 12 months. 
 
3) To measure the per dose protection to type 3 poliovirus in children aged 
between 6 and 12 months of age immunized with trivalent oral poliovirus 
vaccine. 
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4.  LITERATURE REVIEW 
This literature review consists of two parts. First, an introduction of poliomyelitis, 
poliovirus and poliovirus vaccination is given. The second part contains focuses 
on the available literature with respect to evidence for poor immune response to 
OPV in India and factors influencing this poor immune response. 
 Polio – historical perspective 
It appears that polio infection has for a long time been endemic among human 
populations. For example, a stone plate discovered from Egypt, depicts a man with 
a stick as a walking aid. The right leg of this man appears thinned (6). Among 
medical historians this has generally been interpreted as a sign that this man 
suffered from polio sequelae (6). Descriptions of cases that might have been due to 
polio have been reported from ancient 
Rome, among them at least one Roman Emperor (5). 
 
Figure  4.1. Stone plate from Egypt supposedly depicting a man suffering from polio 
complication 
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There are no credible reports of polio from ancient Indian sources, but it may be 
assumed that if polio infection was prevalent in ancient Egypt, then it might also 
have been present in ancient India. 
Perhaps the first person offering a detailed description of symptoms and signs 
compatible with polio infection might have been proposed by the English doctor 
Underwood in the late 1700s. An early published report of probable polio infection 
was given by a German doctor (Jakob Heine) in the mid 1800s, who described Polio 
infection primarily as a paralysis of the lower extremities (7).  A little later, towards 
the end of the 19
th
 century, a first description of a polio epidemic was made by Karl 
Oskar Medin, a Swedish doctor of child diseases (7).  For some time in Europe, 
polio infection was even known primarily as Heine-Medin Disease (7).  
It is thought that polio infection underwent a change in its epidemiology during the 
19
th
 century. Throughout much of human history polio infection may have been 
largely endemic. Because of the fact that polio infection is asymptomatic or only 
has minor unspecific symptoms, severe clinical cases might have been perceived 
as unconnected and sporadic before the 1800s. Reports of outbreaks and large 
scale epidemics of polio infection only occurred towards the end of the 19
th
 
century (6). 
Throughout the late 19
th
 and the first half of the 20
th
 century numerous reports from 
North America and Europe suggested that polio infection had evolved into an 
epidemic infection, with large scale outbreaks occurring especially in summer 
months (8). It is not quite clear why this change from endemic to epidemic polio 
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infection occurred in these areas, and whether similarly, regions outside Europe and 
North America also experienced epidemics in this time. It has been suggested that 
socio-economic changes occurring during the industrial revolution in the West may 
have led to more crowded living conditions and poor sanitation associated with a 
high exposure to faecal-orally  transmitted pathogens such as polio viruses (6). 
Further, inefficient centralized systems of drinking water provision such as piped 
distribution systems may have facilitated transmission at large scale (9). 
The contrarian view is that it was in fact improved sanitation towards the mid 20
th
 
century in the West that reduced exposure and consequently immunity to polio in 
small children who are partially protected by maternal antibodies and in case of 
infection mostly develop unapparent or mild disease only. This may have meant 
that the age range of infection was pushed towards older children and adults who 
are at higher risk of severe disease, thus leading to epidemics of paralytic polio (5, 
6, 8). 
It was due to the epidemic nature of polio infection in the early 20
th
 century, and 
perhaps the fact that prominent figures such as President Roosevelt in the US were 
afflicted by polio infection, that enhanced efforts to develop a potent vaccine 
against polio were made. Polio affected all population strata, not just poor and 
disenfranchised people (9). 
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Polio – pathogenesis and the natural course of infection  
Polioviruses belong to the subgroup of enteroviruses within the large family of 
Picornaviruses, RNA viruses. Enteroviruses such as polioviruses temporarily live 
in the gastrointestinal tract, and are to survive the acidic environment of the 
stomach which is a requirement for successful infection of a new host (9). Three 
distinct poliovirus serotypes are known: P1, P2, and P3. There is little cross-
immunity among these three types. Infection and subsequent immunity to one 
type does not lead to meaningful immunity to the other types (8, 9). 
 
Figure 4.2 Photo of poliovirus under the electron microscope. 
Infection with polioviruses occurs through the mouth. The virus then multiplies in 
the upper respiratory tract and in the gastrointestinal tract, before the onset of 
symptoms. Polioviruses then enter local lymph nodes and Peyer plaques in the 
intestines, later going into the bloodstream (8).  From here they invade the central 
nervous system, in particular the motor neurons cells of the anterior horn of the 
medulla. This then leads to the typical symptoms of flaccid paralysis (8). 
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The incubation period for polio ranges from just 2 to up to 35 days (9). The 
incubation period appears to be longer for paralytic polio infection as compared to 
minor illness (9). 
Only about 28% of Polio infection is thought to be associated with disease 
symptoms (Figure 4.3). Most infected have only few symptoms like 
fever, generalized fatigue, headache, and gastrointestinal symptoms such as 
vomiting or diarrhea. Some neck stiffness and myalgia may also occur which may 
be signs of minor CNS infection and aseptic meningitis (9). Most infected persons 
recover completely within 14 days. Less than one percent of infected children 
experience flaccid paralysis, most often in the legs (spinal paralysis) and less 
commonly of muscles innervated by cranial nerves such as the diaphragm (bulbar 
paralysis). It has been estimated that about 80% of paralytic polio is spinal only, 
2% only in the bulbar region, and perhaps 19% affecting both spine and bulbar 
region/brainstem (9). 
 
 
Figure 4.3 Potential outcomes of infection with polio virus. 
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Bulbar/brain stem involvement may lead to serious disease and death. Overall, 
between 2 to 5% of children that have developed paralytic polio may die. The 
figure is higher for adults (15% to 30%). In general mortality is much higher in the 
presence of bulbar involvement (up to three quarters of cases). 
Decades following primary polio infection the so-called post-polio syndrome may 
occur (10).  It is characterized by neurological symptoms such as newly developing 
weaknesses, atrophy of muscles, dysphagia, dysphonia, or even respiratory failure. 
Musculoskeletal symptoms such as muscle pain, pain in the joints, or scoliosis may 
occur. Often, general symptoms such as generalized fatigue and intolerance to cold 
is experienced by these patients (8). 
Transmission 
Perhaps the most crucial fact about polio epidemiology is that transmission like 
that of smallpox is restricted to human beings (6). This makes polio a suitable 
target for eradication.  
Transmission occurs by the faecal-oral route. Hence polio is prone to occur under 
poor hygienic and sanitary conditions (9). In cold climates polio is occurring 
particularly during the summer months. In hot climates transmission is more 
constant throughout the year (9). 
Polioviruses are highly communicable. Seroconversion occurs in up to 90% to 
100% of susceptible household contacts. Infected persons shed substantial amount 
11 
 
of virus between 8 to 10 days before beginning of symptoms and for a similar 
period afterwards. Shedding may continue for up to 3 to 6 weeks after onset of 
symptoms (11). 
While infected persons shed large amounts of virus through their faeces, immune 
competent persons completely eliminate the virus after a few weeks. This means 
there are no chronic asymptomatic carriers of polio viruses in healthy individuals. 
However, in immune deficient people such as HIV infection, polio viruses may 
not be cleared from the body and viral shedding may continue chronically (11). 
This may have important implications for the post-eradication/post-elimination 
phase as immune-compromised individuals may represent an ongoing reservoir, 
which highlights the importance of keeping up vaccination in the population for a 
long time after eradication (12). 
Vaccination against Polio 
There are two classes of polio vaccine for use in the general public. 1) Inactivated 
poliovirus vaccine (IPV), an inactivated injectable vaccine, and OPV, a vaccine 
formula that contains attenuated live polio viruses. These live viruses can revert to 
a virulent form (Figure 4.4), causing vaccine-associated paralytic polio (VAPP) 
(3). 
Oral polio vaccine is a combination of  three live attenuated poliovirus serotypes 
(Sabin types 1, 2 and 3) and was  introduced in 1961(9). OPV was first developed 
as monovalent formulations against the three serotypes separately and used from 
the early 60s, and later from the mid 60s as a trivalent vaccine. OPV replaced IPV 
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as it is cheaper, can be given orally and may induce a longer lasting immunity 
(13).  Since polio serotype 2 appears to be no longer circulating worldwide and 
type 2 is associated with VAPP, the trivalent OPV is being replaced by bivalent 
OPV that no longer contains serotype 2 (3).  A rare but serious adverse effect of 
OPV is vaccine-associated paralytic poliomyelitis(VAPP), which is clinically 
similar to polio caused by wild poliovirus(WPV), with features of neurovirulence 
(14). 
OPV viruses are found in the stool for up to 6 weeks after vaccination. Most of the 
virus shedding happens in the first 2 weeks post-vaccination. Vaccine viruses are 
able to spread to close contacts of vaccine recipients when they come into contact 
with faecal material containing the vaccine virus. These contacts may even 
develop VAPP if they themselves are not vaccinated (3). 
Inactivated Poliovirus Vaccine was in use in the US and other countries from 
1955(3). Scandinavia and Netherlands have, with IPV alone, managed to eradicate 
polio(9). IPV was largely replaced by OPV from the 1960s. Post-elimination its 
use became the vaccine of choice in the US and in many European countries, as it 
does not cause VAPP. IPV is made from inactivated (killed with formalin) wild-
type poliovirus strains of each serotype. Current IPVs are delivered either as stand-
alone trivalent vaccine or as part of a combination vaccine alongside DPT 
(diphtheria, pertussis and tetanus) with or without Haemophilus Influenzae B 
(HiB) or Hepatitis B(15). 
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Figure  4.4 Schematic diagram of the poliovirus showing possible mutations in 
OPV strains that may cause reversal to a neuropathogenic strain. Vaccine derived 
polioviruses have mutations in the V Domain of a non-coding region. They also 
have at least one mutation in the capsid region at the other end. The polio types are 
marked in parenthesis. From Minor(15) 
 
Although IPV does not induce mucosal immunity, it has the advantage of not 
causing live-virus-associated risks such as VAPP and has very transient and 
minimal adverse effects (3).   Disadvantages of IPV use include the inconvenience 
of an injectable vaccine and the need for skilled personnel to deliver injectable 
vaccines.  The other disadvantage is the need for containment of manufacturing 
areas in view of risks associated with WPV, which is needed to produce IPV. 
Attenuated Sabin strains are in turn being developed to prevent retransmission in a 
post-elimination era (16). 
 
 
14 
 
Table 4.1 Immunisation schedule in India 
VACCINE INFANTS CHILDREN 
BCG Birth/ as early till 1 yr  
HEPATITIS B 
1,2,3 
Birth/ as early till 24 hrs; 
6,10,14 wks 
 
OPV 0 
1,2,3,4 
Birth/ as early till 15dys; 
6,10,14 wks 
 
DPT 1,2,3,Booster 6,10,14 wks; 16-24 months 
MEASLES 1,2 9 months (completed) – 12 mo 16-24 months 
VITAMIN A 9 months Every 6 months (2
nd– 9th dose) 
JAPANESE 
ENCEPHALITIS 
 16-24 months 
TT  10yrs & 16yrs 
 
The current Government of India vaccine schedule (Table 4.1) prescribes 5 doses 
of OPV for children in the country: at birth, at 6, 10 and 14 weeks, and one booster 
in 16 to 24 month-old children.   
Elimination of Polio in India 
Until quite recently there was a lot of skepticism as to the potential for eliminating 
polio infection in India (17). As late as 2004 some critics called a polio-free India 
a “distant dream” (16, 18-20). Reasons for skepticism were partly operational and 
partly based on immunological grounds (16, 17). The latter reason is related to the 
topic of this thesis, i.e. the finding that in low income settings, many children 
remain susceptible to polio even after administering many doses of OPV (21). 
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Nevertheless, India was declared as no longer endemic for polio in 2012 (22). 
India was declared polio-free in early 2014, after having experienced no case of 
polio for three consecutive years (22). Milestones in the elimination-drive of polio 
in India are given in Table 4.2. 
Table 4.2  Milestones in the elimination of polio in India. 
1988 Target for polio eradication by 2000 set by World Health Assembly (WHA)  
1993/1994 Tamil Nadu and Kerala States - special drives conducted to administer polio vaccines. 
1994 Delhi State conduct 2 Polio vaccination drives. 
1995/96 National Days (NIDs) - polio vaccination, 2 conducted. 
1996 Vaccine Vial Monitor used 
1997 National Polio Surveillance Project set up as WHO and Govt of India collaboration. 
1999 Last case of wild polio virus type 2 (WPV2) -  Aligarh, U.P. 
1999 Polio drive: changed booth activity to house to house coverage. 
2002 Social Mobilization Network  - set up for community mobilization. 
2005 Monovalent oral polio vaccine (mOPV) used 
2010 Bivalent oral polio vaccine (bOPV) used for polio campaigns in India. 
Nov 2010 Last reported wild polio virus in sewage sample - Mumbai, India 
22 Oct 2010 Last case of wild polio virus type 3 (P3) -Pakur, Jharkhand. 
13 Jan 2011  Last case of any type of wild polio virus (P1) - Howrah, West Bengal 
25 Feb 2012 India no longer polio endemic country ( removed WHO list) 
 
Polio vaccination using OPV was done in Mumbai from 1964 and in Vellore from 
1965. Systematic vaccination with OPV started in the late 1970s under the 
Extended Programme for Immunisation (EPI) scheme (23). As can be seen in 
Figure 4.5, the number of polio infections declined continuously from the late 80s. 
The decline went in parallel with that of other vaccine preventable conditions (24). 
16 
 
Elimination of polio in India required an intense, well-planned and coordinated 
effort to be sustained for years and there were many setbacks (24).  Enhanced 
efforts, also known as Supplemental Immunization Activities (SIA) to eliminate 
polio were made from 1995 (21). This included National Immunization Days and 
large-scale additional campaigns in endemic areas of India such as UP and Bihar, 
where vaccine coverage was traditionally low (21). Estimated 2.3 million field 
staffs were employed from the year 2000 to vaccinate millions of children. 
Particular efforts were made to reach pastoral populations and migrants, including 
children of migrant workers travelling for example by train (23). 
 
Figure 4.5 Trends in case numbers of polio and other vaccine preventable 
conditions. From (21) 
For much of the campaigns from 2005, monovalent OPV (type 1 and type 3) was 
used, as these were more effective than the trivalent OPV (21). However, under-use 
of OPV type 3 left children susceptible to type 3 (Figure 4.6). Hence, from 2010, in 
the final drive for elimination, bivalent OPV containing type 1 and 3 were introduced 
(8). 
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Figure 4.6 Cases of polio wild types type 1 and type 3 during 2010 and 2011.  
 
India is close to countries that still report polio cases and that, mainly for political 
reasons and internal unrest may remain polio-endemic for some time, namely 
Pakistan and Afghanistan (Figure 4.7). India thus remains at high risk for re-
introduction of wild poliovirus (WPV) (8). Because of this fact, maintaining a high 
immunity against polio infection at population level is of utmost importance and 
the topic of this thesis. Efforts to maintain high immunity are outlined in the next 
section. 
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Figure 4.7 Polio endemic countries and countries at high risk of wild-polio virus 
outbreaks. 
 
Maintaining immunity at population level in the post-elimination phase 
Several factors specific to polio and polio vaccination explain why it is crucial that, 
after elimination of polio in India and even after global eradication, a high level of 
immunity against polio virus at population level will be required for many years.  
First, polio viruses including vaccine derived polio viruses exhibit a certain amount 
of environmental stability (25), although they are inactivated by sunlight and high 
temperatures (11). More importantly, the continuing possibility of conversion of 
attenuated polio viruses used for vaccination to more virulent forms means potential 
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exposure to susceptible individuals as long as OPVs are in use. It has further been 
shown that immune-compromised individuals can serve as a long term reservoir for 
polioviruses, either vaccine-derived or wild types (24). 
Increased international travel means that polio viruses endemic in one country may 
quickly be introduced into other countries that are free of polio transmission. 
Several outbreaks of polio have occurred in this fashion (Figure 4.7 ) (24). During 
the past ten years, 40 countries experienced outbreaks of poliomyelitis following 
importation from polio-endemic countries (26, 27). 
In 2013, an outbreak occurred among children in Somalia, which had been free of 
polio since 2007(28). The outbreak also led to cases of polio in neighbouring Kenya 
which had also been free of polio for several years. Wild type poliovirus was 
detected in sewage samples across a multitude of environmental sampling sites in 
Israel in 2013. The virus was identified to have originated from Pakistan and 
introduced into Israel via Egypt. Although no cases of flaccid paralysis have 
occurred in Israel since detection of poliovirus, this case highlights the potential for 
the virus to cross international borders quickly and insidiously (29). 
A detailed report about an outbreak of polio in Xinjiang province in China where 
about 50 cases of polio infection were identified by public health authorities (30). 
Again the virus appears to have originated from Pakistan. The authorities responded 
with a large scale containment effort that included 5 rounds of vaccination with 
monovalent and trivalent OPV, alongside enhanced surveillance. The costs for 
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containing the outbreak were about 25 million USD highlighting the immense 
logistics and costs involved in responding to outbreaks(24). 
If a high level of immunity needs to be maintained for some time to reduce the risk 
of re-introduction of wild type poliovirus the question arises as to what vaccine 
should be used to achieve this. OPV is associated with the risk of developing 
vaccine derived polioviruses and VAPP. Hence OPV cannot eradicate polio on a 
global scale. As long as children are vaccinated with OPV the risk of polio will 
remain (13). Hence the shift from OPV to IPV is seen as mandatory to achieve 
true eradication. A phased approach is likely to take place in the majority of 
countries that are still using OPV(13). In the long run, to fully eradicate polio, only 
IPV may need to be used, as is already the case in many high income countries, 
where the higher costs of IPV are not an issue. 
WHO has developed the Polio Eradication & Endgame Strategic Plan 2013-2018 
outlining the rationale behind switching from trivalent OPV to bivalent OPV, 
which leaves children susceptible to type 2 (both wild type and vaccine derived). 
To prevent this, it is recommended to add one dose of IPV to the schedules, which 
contains antigens of all three polio serotypes thereby protecting against type two 
after switching to bivalent OPV (31, 32). IPV has been shown to boost mucosal 
immunity to polio after OPV (33). 
A range of operational issues in vaccine delivery has been noted that need to be 
consistently tackled to maintain a high immune status in the population. In a 
recent study looking at immunization coverage in an urban population in Tamil 
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Nadu, routine immunization coverage was found to be 81% (34), indicating 
possible gaps in operational systems in providing adequate doses of polio.  New 
initiatives are being evaluated, such as mobilizing existing community health 
worker structures (2). 
Evidence and risk factors for the poor immunity to polio after OPV in low 
income settings 
The search was done in PubMed without restriction to year of publication. The 
search was conducted up to August 10
th
 2015 Articles published beyond this date 
were therefore disregarded. Papers were restricted to the English language. Papers 
were eligible if they contained original field research or were review articles 
thereof. Reference lists of identified articles were searched for further articles for 
inclusion. The following key words were used for the search in this section: 
[polio* OR OPV] AND “Vaccine efficacy” AND [India OR Africa]; [polio* OR 
OPV] AND  immun*; [polio* OR OPV]  AND mucosa*; [polio* OR OPV]  AND 
diarrh*; [polio* OR OPV]  AND enterovir*; [polio* OR OPV]  AND 
malnutrition; [polio* OR OPV]  AND enteropathy. 
Issues with reduced VE in low income settings were first reported in India 
including Vellore. An early study of poor response to OPV was published by John 
and colleagues (2). This study clearly found that immunogenicity to OPV is much 
lower in India than could be expected based on data from high income countries. 
The was study done, in  children aged 3 months and 6 years, in Vellore, Tamil 
Nadu. In 191 children before a first dose of OPV, 28%, 7% and 6% of children 
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were already seropositive to types 1, 2 and 3, respectively.  Among the 
seronegatives, trivalent OPV produced seroconversion in 35% to type 1, 75% to 
type 2 and about 50% to type 3 after having received 2 doses 2 months apart (35). 
The clinical relevance of this poor vaccine response could be demonstrated in 
further studies showing that poliomyelitis occurs regularly in children who 
previously received OPV (36). 
A study from Delhi demonstrated seroconversion after three doses of trivalent 
OPV in children of about 65%, 80% and 60% to polio types 1, 2 and 3 
respectively (37). The study further showed that increasing the vaccine dose given 
at each vaccination does not influence seroconversion. Similar figures were found 
in an earlier study from Delhi published by Ghosh et al (38). A study from 
Mumbai published in 1977 by Pangi et al showed an equally poor response to oral 
polio vaccine (39). 
A study from Nigeria estimated vaccine efficacies per dose of monovalent type 1 
OPV and trivalent OPV against paralytic poliomyelitis (type 1) to be 67% and 
16% (95% CI, 10 to 21), respectively (40). This highlights the poor efficacy 
especially of the trivalent vaccine, probably due to interference among the vaccine 
strains (39). The estimated efficacy of trivalent oral poliovirus vaccine per dose 
against type 3 paralytic poliomyelitis was also very low at 18% (41). A second 
study from Nigeria found an effectiveness against vaccine derived polio virus 
infection to be 38% of the trivalent OPV, which was higher than the efficacy 
found against wild-type poliovirus type 1 (13%) and type 3 (20%). Similar to the 
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above studies in India, the study found that frequent repetition of vaccination 
substantially improves efficacy (42). 
A study in Uttar Pradesh found that in places with ongoing poliovirus 
transmission, the protective efficacy of monovalent OPV against type 1 was about 
30% per dose compared with 11% for the trivalent OPV (43). A randomised 
controlled trial in India found that bivalent OPV (types 1 and 3) was again far 
more efficacious than trivalent OPV, and resulted in a comparable immune 
response compared to the monovalent OPV against type 1 and type 3 given 
separately (40, 44). 
Risk Factors for Poor immune response to OPV 
Many factors have been studied that may influence immune response following 
OPV in children in low income settings(45). The lower immunogenicity, in both 
humoral and mucosal immunity, in India and other countries, where a substantial 
proportion of the population live in low income settings, calls for further research 
into risk factors associated with non-seroconversion (46-50). The main factors that 
have been studied are listed below (Table 4.3): 
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Table 4.3  Overview of potential risk factors for a reduced immune response against 
oral poliovirus vaccine. 
Maternal factors References 
 Breastfeeding (48, 51, 52) 
 Maternal antibodies (48, 53, 54) 
Childhood infections 
 Diarrhea (2, 46, 50, 55, 56) 
 Non-polio enterovirus co- infection (57) 
Child nutritional factors 
 Malnutrition (54, 58-61) 
 Environmental enteropathy (Tropical Enteropathy) (62, 63) 
Child demographic factors 
 Age (64) 
 Gender (50, 52). 
 
Breastfeeding and maternal antibodies 
There is a debate with regard to the effect of exclusive breastfeeding on immune 
response to OPV. A study conducted in India and published in 1980 suggested that 
exclusive breastfeeding may reduce immune response to polio types 1, 2 and 3 by 
33%, 17% and 12% respectively (49). The mechanism may be maternal 
antibodies. Similarly, an earlier US study found that breastfeeding may reduce 
vaccine immune response by about 25% (48). A study conducted in Brazil 
suggested that high levels of maternal antibodies to the three poliovirus types led 
to a higher chance of vaccine failure (48). In this study, breastfeeding was 
25 
 
associated with a marginal reduction in immunogenicity to poliovirus types 1 and 
2 and a more marked reduction (of 30%) to type 3 (54). A study done at Dhaka 
evaluating reasons for failure to mount an immune response to OPV found a short 
duration of breastfeeding to be a significant risk factor.  Each additional month of 
exclusive breastfeeding increased OPV titres (46). 
By contrast, a study in Uganda comparing breastfed and formula fed children 
found no evidence for a reduction in the immune response to monovalent OPV 
type 1, and if anything even an increase in immunogenicity by about 20% (47). 
Similarly, a study in Tunisia estimated a similar increase in immunogenicity (52).  
However, the last two studies were fairly small, with wide confidence intervals 
that make it difficult to interpret the findings. However, another study also 
supported this finding with higher anti-polio IgA responses in those who were 
exclusively breastfed (51). A trial in Egypt found that high maternal antibodies 
clearly reduced immune response to OPV in newborns. However, this study also 
found that in children with high maternal antibodies to polio, monovalent OPV 
was much more effective in achieving seroconversion than trivalent OPV (46% 
versus 21%) (40). Overall, the effect of breastfeeding on immunogenicity of OPV 
appears to be small, especially when monovalent OPV is used.  
Diarrhoea 
It is biologically plausible that diarrhoeal disease episodes concurrent or preceding 
OPV may affect the efficacy of vaccination. The mechanism may be that gut 
clearing of OPV viruses may be enhanced during diarrhoea as stool passage time 
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is reduced. Further, non specific immune responses (e.g. by cytokines or 
complement factors) that is elicited by concurrent gastrointestinal infection may 
suppress the OPV polio vaccine strains in a way that prevents or lowers the 
stimulation of specific antibody production (48). However, evidence appears 
conflicting. 
A study from Gambia found some evidence that diarrhoea reduced the 
immunogenicity to type 3 poliovirus by about 15% while seroconversion to type 1 
and 2 were hardly affected (48).  Similarly, a study from Brazil conducted jointly 
with the Gambia study suggested that seroconversion to type 3 poliovirus is 
reduced by 18%. Immune response to type 2 was reduced by 7% whereas immune 
response to type 1 was not affected (53). A study from Bangladesh conducted in 
1996 among 6 to 16 weeks old children found that seroconversion after the first 
dose of trivalent OPV was reduced in the presence of concurrent diarrhoea by 34% 
with regard to type 3 and 26% with regard to type 2 poliovirus. Again there was no 
effect on type 1 poliovirus immune response (53). Seroconversion was however 
hardly impaired in children with diarrhoea who received the third dose of trivalent 
OPV (54). 
The already above mentioned study done at Dhaka evaluating reasons for failure 
to mount an immune response to OPV also found diarrhea to be a significant risk 
factor (65). Children with two or more episodes of gastrointestinal infection during 
the first months after birth had more than twice as high a risk to fail to mount an 
adequate immune response to OPV as those who had only one episode or no 
episode at all (p=0.02).  
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A study from Brazil found that diarrhoea reduced seroconversion to type 1 (-14%), 
type 2 (-64%) but not to type 3 after the second dose of OPV. There were only 
small and inconsistent effects of diarrhoea on immune response to the third or 
fourth dose of OPV (59). A serosurvey conducted in Pakistan found that diarrhoea 
in the past six months to be associated with lack of seroconversion after OPV (40). 
On the whole the results suggest that diarrhoea may considerably reduce the 
chances of seroconversion after the first and second doses of OPV, but that the 
efficacy of subsequent doses to elicit an adequate immune response is hardly 
impaired.    
The effect of concurrent infection with enteroviruses other than polio 
Concurrent infection with enteroviruses other than poliovirus has been proposed as 
a possible factor that may reduce immune response to oral poliovirus vaccines. 
Similar to other gastrointestinal infections, these enteroviruses may cause a non-
specific immune reaction that may suppress poliovirus vaccine strains. In addition 
to other gastro-intestinal pathogens, enteroviruses other than polio may due to 
phylogenetic closeness to polioviruses also cause a specific antibody response 
leading to the shedding of antibodies that may cross-react with OPV antigen (2). 
A number of studies have been conducted to examine this question. An early study 
conducted by John and Jayabal in Vellore exploring the effect of concurrent 
enterovirus infection on shedding of polio vaccine viruses post OPV found no 
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evidence that enterovirus infection impaired infection with the vaccine strains. 
Seroconversion however was not measured in this study (55). 
In a study from Mexico on rural Mayan children (a poor setting) found that 
concurrent enterovirus infection reduced immune response to OPV by as much as 
43% (50). A study from India published by Idris and colleagues found that 
enterovirus infection reduced seroconversion to OPV by about 15% for all three 
vaccine strains (56). Similar observations were made by Swartz and colleagues in 
Israel who found non-polio enteroviruses to reduce seroconversion following OPV 
by up to 47% (type 1), 17% (type 2) and 29% (type 3) (56). However, their results 
were not consistent and were restricted to one season, while in a previous season, 
hardly any impact of enteroviruses were found. Seasonal changes in enterovirus 
force of infection may explain these conflicting trends (46). 
Domok and colleagues found in a study in Uganda that non-polio enteroviruses 
interact with monovalent type 1 OPV and reduce seroconversion by 24%. Of 38 
children with concurrent enterovirus infection 45% seroconverted, whereas in the 
49 children without concurrent enterovirus infection 59% seroconverted. 
However, statistical support for this finding was low (p= 0.2). The authors also 
report that repeated vaccination with OPV can markedly reduce the deleterious 
effects of enterovirus co-infection (47). 
Triki and colleagues found in their small sample of 121 Tunisian children that 
coinfection with non-polio enteroviruses was prevalent in 50% of children that 
failed to mount an adequate immune response. By contrast, none of the children 
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with an adequate immune response was found to be positive for non-polio 
enterovirus infection (66). 
Malnutrition 
It has been generally suggested that malnutrition plays a minor role in reducing 
seroconversion to OPV and other vaccines (54). The literature on OPV provides 
with mixed results. In the study from Dhaka in Bangladesh mentioned above, 
malnourished children (Weight for age z score <-2) had markedly lower OPV 3 
titers (difference in medians 0.9, p=0.03) than children without signs of 
malnutrition (58). In multivariable quantile regression analysis, compared with 
malnourished children, normal children had 2.35 (95% CI: 0.66–4.03, p = 0.0065) 
and 1.11 (95% CI: 0.31–1.90, p = 0.0063) higher OPV titer 3 measures at the 25th 
and 50th percentiles of OPV response, respectively. 
In a study conducted in north India to assess seroprevalence of antibodies to 
different types of poliovirus, malnutrition was found to be associated with a lower 
seroprevalence of antibodies to type 3 (59).  In a study from Pakistan stunting was 
clearly found to be associated with failure to seroconvert (57). Similarly, a 
serosurvey from Pakistan in children with at least 7 documented doses of OPV, 
protein-energy malnutrition was strongly associated with lack of seroconversion 
(60). 
A randomized controlled trial in Pakistan also found that severely malnourished 
children were at high risk of failure to seroconvert after bivalent OPV alone (67, 
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68). Interestingly, this trial found that combining OPV and IPV in these children 
led to an immune response comparable to children that were not malnourished. 
 
Environmental Enteropathy 
Studies in malnourished children and adults temporarily living under poor 
hygienic conditions have suggested a direct link between exposure to poor hygiene 
and chronic inflammatory changes in the intestines that are characterized by a 
decrease in the villous height, infiltration of inflammatory cells, increased 
intestinal permeability (results in the impairment of the gut’s barrier function 
against unwanted products), and a worsening of the intestinal absorption of 
essential nutrients (67, 68).  This chronic condition is known as tropical or 
environmental enteropathy (67, 68).  
Evidence that environmental enteropathy may play an important role in the 
development of undernutrition in low-income settings is mounting (69, 70). 
Studies in the Gambia have suggested that environmental enteropathy may explain 
about half of the growth faltering in infants (61). 
There is also some evidence that environmental enteropathy may impair immune 
response to oral poliovirus vaccine. A study from Bangladesh found that in 
children with abundant Bifidobacterium  infantum colonization in their guts, 
immune response to polio and BCG vaccination (measured as the specific T cell 
response) was higher than in children with reduced Bifidobacterium infantum  
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predominance, which is a feature of environmental enteropathy. The authors 
speculated that vaccine effectiveness may be enhanced by promoting the intestinal 
symbiotic flora (62). An experimental study conducted in health adult volunteers 
found that probiotics enhance immune response,  by increased poliovirus 
neutralizing antibodies, which again enhanced the shedding of poliovirus-specific 
IgA and IgG in serum (71). 
 
 
Figure 4.8 Environmental Enteropathy 
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On the whole these studies suggest that environmental enteropathy may be an 
important factor in limiting seroconversion in children in poor and unhygienic 
settings (63), but more studies are clearly needed to confirm this suspicion. 
Age, socio-demographic and geographic factors 
Studies done in low socioeconomic settings in Pakistan found age, total and 
campaign OPV doses to be associated with higher seroprevalence.  Seroconversion 
rates at birth were found to be low to poliovirus type 1 after mOPV1 or tOPV 
given at birth but high for all formulations of mOPV1 given at age 30 days, with a 
possible explanation linked to the presence of maternal antibodies (72). However, 
a large variability exists in seroconversion rates at birth, which is not completely 
understood (73). 
In India, variations in mucosal immunity was also noted to differ with location, 
serotype and vaccine formulation (48, 74), with the immunogenicity of OPV also 
appearing to vary with the season (64). 
Gender 
The effect of gender on seroprotection to poliovirus following vaccination is 
unclear.  In a seroprevalence study conducted in Nigeria, number of OPV doses, 
maternal education and gender were associated with seroconversion (52).  
A recent study has revealed one dose of OPV and BCG to be associated with 
higher excretion of gut cathelicidin (LL37) in infants at 6 week of age. Girl 
infants were found to have higher human-beta-defencin2 as compared to boys 
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(HBD2) (75).  HBD2 is a member of the defensin family of antimicrobial peptides 
that plays important roles in the innate and adaptive immune system (76).  LL37 
plays a similar role (77).  
Several studies with other vaccines have shown differences in gender.  One study 
found females had higher neutralizing antibody titers following smallpox vaccines 
than males (78-83).  Sex-differential adverse effects have also been noted in 
vitamin A supplementation, DPT, measles vaccine and anthrax vaccine (84, 85).  
Non-specific effects of vaccination have been noted to vary in gender in a twin 
pair study (86).  Women have also had more reactions to adsorbed anthrax 
vaccine as compared to men (87) and had higher titres to measles vaccines (88).  
In summary, the literature review suggests that coinfection with enteroviruses 
other than polio may be the strongest measureable factor associated with failure to 
seroconvert that has been studied so far. However, it also seems that repeated 
doses of OPV can overcome this problem.  
The effect of malnutrition on OPV efficacy is not well understood. Currently 
available studies however, appear to exclude large effects, but more research is 
needed to confirm this. Environmental enteropathy has not been well studied as a 
risk factor for failure to seroconvert following OPV. More research is needed in 
this emerging field of research. 
The risk factors for failure to be seroprotected following immunization are 
equivocal and to our knowledge not well established.  Our intent is to evaluate a 
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few risk factors including protein energy malnutrition, operational and socio -
demographic factors. We are unaware of literature from this region or from the 
rest of India that have evaluated these factors in the past 20 years. The 
demographic and nutritional transition that the population has undergone and 
increasingly conflicting evidence on the role of malnutrition and gender on 
immune responses to vaccine makes us believe it is particularly relevant that these 
factors be evaluated afresh. 
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5.  METHODOLOGY 
Study Setting 
The study was conducted in Vellore district in the southern Indian state of Tamil 
Nadu. Three blocks were chosen for the study based on the fact that an ongoing 
OPV surveillance system in the context of an ongoing clinical study (EVI trial, 
http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=9069) in these areas 
offered the chance to easily obtain a sampling frame for the study. The areas 
included in the study were Vellore Town, as well as Kaniyambadi and Anaicut 
Blocks. The study area in Vellore Town included a mix of predominantly urban 
neighbourhoods some of which consisted of formal settlements while others 
resembled unplanned urban slums. Low income neighbourhoods predominated in 
the OPV surveillance sample used as a sampling frame, and was not a 
representative sample of the whole of Vellore town. Kanyiambadi and Anaicut 
blocks are mainly rural where agriculture predominates around smaller sized 
towns. The furthest distance travelled was to Pallikonda in the Anaicut block, 
which was approximately 23 km away. Recruitment and data collection took place 
between April and May 2015. 
Study Design  
This study was performed as a case control study on seropositive and seronegative 
children previously identified during screening for recruitment of seronegative 
children to the EVI trial.  Children between 6 and 18 months are considered to 
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have the highest risk of neuroparalytic poliomyelitis and ascertaining protection in 
this age is important.  
Selection of Cases and Controls 
Cases definition: All children between the ages 6 – 12 months in the Vellore and 
Kaniyambadi block who were recruited as part of the EVI study and were found to 
have antibody titres less than 1:8 dilution to type 3 OPV. 
Exclusion criteria:  Child who received Inactivated Polio Vaccine prior to blood 
sampling for the EVI study. 
Control definition: Children between 6-12 months from the same study area with 
serum neutralizing antibody titres greater than or equal to 1:8 dilution against type 
3 OPV. 
As part of screening for eligibility in a large pragmatic clinical trial (EVI study) 
that included seronegative infants between 6 and 12 months of age, 8454 infants 
were tested for neutralizing antibodies to type 3 poliovirus. A total of 284 children 
were selected by an independent statistician without details of the antibody test. 
This 284 children  included a random subset of 142 seronegative children 
designated as “cases” and 142 seropositive children designated as “controls”, 
whose status were unmasked only after all data was gathered by the investigator.  
Cases and controls were visited at home and the primary caregiver, following 
informed consent, was administered a structured questionnaire on details 
nutritional anthropometry at home. Although the age group was 6-12 months for 
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the clinical trial, there was an average of 6 months from that point to when this 
case control study was done.  
 
Sample Size 
For the sample size calculation the study was treated as an unmatched case control 
study with 1 control per case, ignoring the stratified matching approach based on 
location. We calculated the sample size to estimate the association of malnutrition 
with failure to be seroprotected. National Family Health Survey -3 indicates 
underweight for age to be 40.2% in children 12-17 months. Since seronegative 
status is sufficiently rare, we assumed this to be the prevalence of malnutrition in 
the control population. If the true odds ratio for seronegative status in 
malnourished subjects relative to well-nourished subjects is 2, we would need to 
study 134 case patients and 134 control participants to be able to reject the null 
hypothesis that this odds ratio equals 1 with probability (power) 0.8.  The Type I 
error probability associated with this test of this null hypothesis is 0.05.  We used 
a Fisher’s exact test to evaluate this null hypothesis. 
 
An odds ratio of 2 was assumed resulting in an expected prevalence of exposure 
among the cases of p1= 0.573.  
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The sample size was calculated using the following formulae: 
 
n = 
   
 
 
           
  
    
 
        
 
 
Assuming 80% power and alpha= 0.05, and a ratio of cases to controls of 1:1 
results in 134 cases and 134 controls.   
 
(P1) =P0*OR/(1+P0(OR-1))=0.573 
 P = (P1+P0)/2= (0.402+0.573)/2=0.4875 
    (1  - P ) =0.5125 
d= P0-P1=0.171 
n  (        *P *  *2/d² 
Power of the study is 8 % i.e     .842 
Alpha error  5% i.e    1.96  
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Data Collection 
Study procedures were implemented as shown in the flow diagram below: 
Figure 5.1 Study Procedure 
 
 
The data collection tool had 3 components:  
1. Structured questionnaire to identify risk factors applied to mothers/carers of 
children included in the study 
2. Recording information on OPV detailed in the children’s Immunization 
Cards 
3. Anthropometric assessments (weight and height/recumbent length) of 
study children to check the nutritional status 
  EVI STUDY 
8454 CHILDREN 
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7451 seropositive 1003 seronegative 
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      284 
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Data entered EPIDATA 
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BLINDED  to 
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Analysis 
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UNBLINDED  to 
INVESTIGATOR 
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Data Management 
Data was entered in Epidata and analyzed using Statacorp, Texus version 12.0  
Data Analysis 
Descriptive statistics were done using bar charts and histograms. Socio-
demographic characteristics of cases and controls were compared using t-test 
(continuous variables), wilcoxon test (ordered categorical variables) and the chi-
square test (binary variables and categorical variables that were not ordered. To 
explore unadjusted and adjusted risk factors for being a case, univariable and 
multivariable analysis using binary logistic regression was performed; odds ratios 
and their confidence limits were estimated. 
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6.  RESULTS 
In the following section, a descriptive analysis is first presented under separate 
sections; demographic factors, parental related factors, birth related factors, breast 
feeding related factors, anthropometric measurements, water and sanitation 
factors, and operational factors. 
This is followed by a risk factor analysis in which a univariable and then a 
multivariable analysis is presented in similar sections. 
 
6.1 DESCRIPTIVE ANALYSIS 
6.1.1   DEMOGRAPHIC CHARACTERISTICS: 
A total of 284 children were recruited in the study.  Among them 142 were cases 
and 142 were controls.  The largest percentage of children were in the 14 month 
age group, with equally high percentages (15%) in the 13 and 15 months age 
group. The mean age in months was 15. 
Mean age was 16 months in the control group and 15 months in the case group. 
(p=0.0009).  
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Figure 6.1 Age Distribution of the Study Population (cases n= 142, controls n=142) 
 
Comparison of cases and controls for demographic factors are shown in Table 6.1 
Amongst both the cases and the controls, about half were male children and most 
were from the rural area. Majority of the children from both the groups lived in 
pucca houses.  
Majority of the children belonged to the most backward class, with 42% amongst 
the cases and 45% amongst the controls, followed by the scheduled class or tribe 
and   other or backward class. Eighty one percent of the children belonged to the 
Hindu religion. 
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Table 6.1. Demographic Risk Factors by Seroprotection Status

 
VARIABLE CATEGORIES 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
 
Gender 
Male 71(50) 79 (56) 
Female 71 (50) 63 (44) 
Residence 
Urban 62 (43.7) 57 (40) 
Rural 80 (56.3) 85 (60) 
Type of 
House 
 
Pucca 105 (73.9) 96 (67.6) 
Mixed 30 (21.1) 44 (31) 
Kutcha 7 (4.9) 2 (1.4) 
 
 
Caste 
OC/BC 34 (24) 30 (21.4) 
MBC 60 (42) 63 (45) 
SC 48 (34) 47 (33.6) 
Religion 
Hindu 113 (79.6) 116(81.7) 
Muslim 24(16.9) 23(16.2) 
Christian 5(3.5) 3(2.1) 
SES 
Upper Lower 44 (31.2) 44 (31) 
Lower Middle 55 (39) 63 (44.4) 
Upper Middle 38 (27) 33 (23.2) 
Upper 4 (2.8) 2 (1.4) 
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According to the Kuppuswamy scale, majority of the children belonged to lower 
middle socioeconomic background, with 39% in the cases and 44.4% in the 
controls. This is followed by the upper lower, upper middle and upper class. There 
were no children in the lower class. 
There is no evidence to suggest a difference between the cases and controls with 
gender, residence, type of house, caste, religion or socio economic status 
(Kuppuswamy scale).  
6.1.2 PARENTAL CHARACTERISTICS: 
Comparison table of cases and controls with regard to parental factors are found in 
Tables 6.2-6.4 
Mean age of the mothers is 25 years, as shown in Table 6.2, with the majority 
completing their high school, 38.7% amongst cases and 36% amongst the controls.  
Majority of the women were housewives, 81.7% amongst cases and 88% amongst 
the controls (Table 6.3).  
Table  6.2 Mother's Age by Seroprotection Status

 
VARIABLE CASE/CONTROL MEAN STD. DEVIATION 
Mother’s Age 
Case (N=142) 25.5 3.9 
Control (N=142) 24.9 3.9 
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The majority of the fathers completed their high school and are mainly unskilled 
workers as seen in Table 6.4  
There is no evidence to suggest a difference between the cases and controls with 
regard to mother’s age, mother’s education, mother’s occupation father’s 
education or occupation.  
Table 6.3 Mother's Education and Occupation by Seroprotection Status

 
EDUCATION 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Illiterate 6 (4.2) 6 (4.2) 
Primary 9 (6.3) 6 (4.2) 
Secondary 44 (31) 33 (23.2) 
High School 55 (38.7) 51 (36) 
Higher Secondary 19 (13.3) 29 (20.4) 
Diploma/Degree/ 
Postgraduate 
9 (6.3) 17 (12) 
OCCUPATION 
Housewife 116 (81.7) 125 (88) 
Skilled 3 (2.1) 3 (2.1) 
Unskilled 19 (13.3) 11 (7.8) 
Service related 1 (0.7) 0 
Business 0 1 (0.7) 
Professional 3 (2.1) 2 (1.4) 
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Table 6.4 Father's Education and Occupation by Seroprotection Status

 
EDUCATION 
CASE 
(N=142) 
n (%) 
CONTROL 
(N=142) 
n (%) 
Illiterate 10 (7) 5 (3.5) 
Primary 19 (13.5) 17 (12) 
Secondary 35 (24.8) 31 (21.8) 
High School 52 (36.9) 56 (39.4) 
Higher Secondary 16 (11.4) 23 (16.2) 
Diploma/Degree/ 
Postgraduate 
9 (6.4) 10 (7) 
OCCUPATION                                             N=141                             N=142                                         
 
Skilled 74 (52.5) 74 (52.1) 
Unskilled 46 (32.4) 44 (31) 
Service related 7 (5.0) 8 (5.6) 
Business 7 (5.0) 14 (9.9) 
Professional 6 (4.2) 2 (1.4) 
Unemployed 1 (0.7) 0 
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6.1.3 SOCIOECONOMIC STATUS CHARACTERISTIC: 
Comparison of the socioeconomic details is shown in table below.  The average 
income per month was between Rs. 4770-7153.  The majority of the cases and 
controls didn’t have any land.  Majority were in the upper middle group as seen in 
the figure below (Figure 6.2). SES did not appear to modify the risk of being a case.   
 
Figure 6.2 Kuppuswamy Scale for SES by Seroprotection Status

 
 
6.1.4 IMMUNIZATION HISTORY: 
The place of receiving their immunization is given in Figure 6.3. Majority of the 
children received their doses at a government hospital with the fourth dose given 
nearly equally at balwadi/school (42%) and at the government hospitals (47%).   
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Figure 6.3 Place of Immunization by Seroprotection status

 
 
Figure 6.4 and Table 6.5 show the number of doses for cases and controls.  
Majority of the children had 4 doses, 52.1% in the cases and 45% in the controls, 
with the difference being statistically significant with a p value of 0.017. 
 
Figure 6.4 Total doses of OPV in cases and controls  
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Table 6.5  Percentage of total doses by Seroprotection Status

 
TOTAL 
NO. DOSES 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
1 1 (0.7) 0 
2 3 (2.1) 0 
3 11 (7.8) 8 (5.6) 
4 74 (52.1) 64 (45) 
5 22 (15.5) 25 (17.6) 
6 30 (21.1) 42 (29.6) 
7 1 (0.7) 3 (2.1) 
6.1.5 BIRTH RELATED CHARACTERISTICS OF THE STUDY CHILDREN 
Birth weights is shown in Table 6.6, Figure 6.5, place of birth in  6.8 and a 
comparison of low birthweight versus normal weight is seen in Table 6.7. 
6.1.5. Birth weight of study children 
The mean birth weight among cases and controls was 2.9 kg (±0.43 and ±0.44)  
respectively, shown in Figure 6.5 . There was no evidence to show a difference 
between the cases and controls (p=0.474). 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
50 
 
 
Figure 6.5 Birth Weight by Seroprotection Status

 
 
Table 6.6 Birth Weight by Seroprotection Status
* 
 
Mean Birthweight (kg) Standard Deviation 
Case (n= 142) 2.9 0.43 
Control (n=142) 
2.9 0.44 
 
A total of 37 children were low birth weight, with 12% amongst the cases and 
14% amongst the controls.  There is no evidence to suggest any difference. 
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Table 6.7 Low Birth Weight by Seroprotection Status* 
 CASES 
 (N= 142) 
n (%) 
CONTROLS 
(N= 142) 
n (%) 
P value 
Low Birth Weight 
(<2.5kg) 
17 (12) 20 (14) 
0.597 
Normal 
>/=2.5kg 
125 (88) 122 (86) 
 
The majority of the cases and controls had a normal birth weight, 88% and 86% 
respectively. There was no evidence to suggest any difference. 
Place of Birth (Govt/Private) of the study children: 
The majority of the cases and controls were born in government hospitals, 68.3% 
and 67.6% respectively.  There was no evidence to suggest any difference. 
Table 6.8 Place of Birth of Study Children by Seroprotection Status

 
 CASES 
(N=142) 
n  (%) 
CONTROLS 
(N=142) 
n (%) 
Government 
Health Facility 
97 (68.3) 96 (67.6) 
Private Health 
Facility 
45 (31.7) 46 (32.4) 
 
The presence of other siblings showed no statistical difference between the cases 
and controls as seen in the Table 6.9.  Majority had either one or no other siblings, 
with no evidence of association. 
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Table 6.9 Presence of other siblings <5yrs age by Seroprotection Status

 
OTHER 
SIBLINGS 
     (<5yr olds) 
CASES 
((N=142) 
n (%) 
CONTROLS 
         (N=142) 
n (%) 
0 68  (47.9) 75 (52.8) 
1 68 (47.9) 62 (43.7) 
2 6 (4.2) 4 (2.8) 
3 0 1 (0.7) 
 
6.1.5. Feeding practices of the study children: 
Comparison of the feeding practices between the cases and controls are shown in 
table 6.10 and 6.11. 
The mean number of months of exclusive breast feeding was 4 months (±2.13), 
with a min of 0 months to a maximum of 19 months. The mean number of 
months of exclusive breast feeding was 4 months (±2.13), with a min of 0 months 
to a maximum of 19 months. The majority of the cases (99.3%) and controls 
(96.5%) were given colostrum.  There is no statistical evidence of any difference 
between the cases and controls with regard to feeding practices. 
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Table 6.10 Feeding Practices by Seroprotection Status

 
FEEDING 
PRACTICES 
DURATION 
(months) 
CASES 
(N = 142) 
n (%) 
CONTROLS 
(N = 142) 
n (%) 
Mean – 
months 
(SD) 
Exclusive 
Breast feeding 
0-3 62 (43.7) 57 (40.1) 
4.0 
(±2.1) 
4-6 69 (48.6) 76 (53.5) 
7-12 10 (7) 9 (6.3) 
≥13 1 (0.7) 0 
Initiation of of 
Complementary 
Feeds 
0-3 20 (14.1) 10 (7) 
5.9 
(±2.2) 
4-6 81 (57) 87 (61.3) 
7-12 40 (28.2) 45 (31.7) 
≥13 1 (0.7) 0 
Initiation of Water 
0-3 25 (17.6) 24 (16.9) 
5.6 
(± 2.2) 
4-6 72 (50.7) 83 (58.5) 
7-12 44 (31) 33 (23.2) 
≥13 1 (0.7) 2 (1.4) 
 
Table 6.11 Feeding Colostrum by Seroprotection Status
* 
 CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Given 141 (99.3) 137 (96.5) 
Not given 1 (0.7) 5 (3.5) 
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6.1.6. MEDICAL HISTORY OF THE STUDY CHILDREN 
Comparison of the medical history with regard to the variables admission, reason 
for admission and presence of diarrhoea at the time of receiving OPV is shown in 
Tables 6.12 - 6.14.  Being admitted did not increase the chance of being a case. 
Table 6.12 Admission to a Hospital by Seroprotection Status
* 
 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Yes 25 (17.6) 24 (16.9) 
No 117 (82.4) 118 (83.1) 
Majority of cases and controls did not have diarrhoea at the time of receiving 
adose of OPV (Table 6.14).  There was no evidence to show any difference. 
 
Table 6.13 Reasons for Admission to the Hospital by Seroprotection Status

 
 
CASES 
(N=25) 
n (%) 
CONTROLS 
(N=24) 
n (%) 
Pneumonia 7 (28) 13 (54.17) 
Diarrhoea 4 (16) 0 
Febrile Seizures 2 (8) 3 (12.5) 
Others 12 (48) 8 (33.33) 
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Table 6.14 Presence of Diarrhoea at the time of receiving an OPV Dose by 
Seroprotection Status
 
 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Yes 2 (1.4) 1 (0.7) 
No 140 (98.6) 141 (99.3) 
6.1.7. ANTHROPOMETRIC MEASUREMENTS OF THE STUDY CHILDREN 
Tables 6.15 – 6.16   show the anthropometric measurements. The z scores between 
cases and controls were found to show some evidence for a difference with regard 
to height for age score, with a difference of 0.2 and a P value of 0.097 as seen in 
Figure 6.6 and Table 6.15. 
 
Figure 6.6 Height for age z scores by Seroprotection Status
* 
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Table 6.15 Mean Z scores by Seroprotection Status

 
Z-SCORE 
SYSTEM 
CASES 
(mean) 
CONTROLS 
(mean) 
DIFFERENCE 
P VALUE 
 
WHZ -0.83 -0.85 -0.01794 0.875 
WAZ -1.26 -1.16 0.094 0.371 
HAZ -1.35 -1.15 0.2 0.097 
 
Comparison of underweight, stunting and wasting (Table 6,16) by seroprotection 
status showed no evidence of any difference.  
Table 6.16  Underweight, Stunting and Wasting by Seroprotection Status
* 
                 CASES  
n (%) 
CONTROLS 
n (%) 
Underweight 
(WHZ<-2) 
18 (12.8)  13 (9.2) 
Stunting 
(HAZ<-2) 
31 (22) 35 (24.8) 
Wasting 
(WAZ<-2) 
26 (18.3) 29 (20.4) 
 
6.1.8. WATER & SANITATION CHARACTERISTICS : 
Factors related to water and sanitation, such as sanitary practices, source of 
drinking water, treatment of drinking water, time taken to reach the water source, 
and treatment of water given to the child at the time of initiating water into the diet 
were looked into.   
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Open defecation was practiced by 50% amongst cases and 47.2% in the control as 
seen in Table 6.17 , followed by private toilets ( cases: 42.3% and controls 46.5%), 
and shared toilets being the least common.  
Table 6.17 Sanitary Practices by Seroprotection Status

 
 CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
TOILET 60 (42.3) 66 (46.5) 
SHARED LATRINE 11 (7.8) 9 (6.3) 
OPEN DEFECATION 71 (50) 67 (47.2) 
 
As shown in Table 6.18, open defecation was more common in the rural area with 
70% as opposed to 18% in the urban area. 
 
Table 6.18  Comparison of the practice of Open Defecation between Rural and 
Urban areas.  
OPEN DEFECATION 
RURAL 
(N=165) 
n (%) 
URBAN 
(N=119) 
n (%) 
Yes 116  (70.3) 22 (18.49) 
No 49 (29.7) 97 (81.51) 
 
Initiation of water to the child was mainly between 4-6 months, cases with 50.7% 
and controls with 58.5%. The majority did not treat the water given to the child at 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
58 
 
the time of initiating water in the feeds, cases with 73.8% and controls with 
64.8%. 
There was some evidence of the treatment of water with being a case (p=0.102).  
 
Table 6.19 Treatment of Drinking Water given to the child by Seroprotection 
Status

 
 CASES 
(N=141) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Treated 37 (26.2) 50 (35.2) 
Not treated 104 (73.8) 92 (64.8) 
 
The source of water was mainly a government supply amongst cases and controls, 
80.3%  and 81% respectively, with the majority of them not treating this water 
prior to drinking .  The source of water was in the majority of the cases and 
controls outside their houses, with access to water less than 5 minutes away in the 
majority of the households, as seen in Table 6.20. There is no evidence to show 
any difference between the above variables between the cases and controls. 
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Table 6.20 Source of Household Drinking Water by Seroprotection Status

 
 CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Piped(govt) 114 (80.3) 115 (81) 
Borewell 8 (5.6) 6 (4.2) 
Dug well/ 
Spring water 
1 (0.7) 1 (0.7) 
Water tanker 7 (4.9) 7 (4.9) 
Bottled 12 (8.5) 13 (9.2) 
 
Table 6.21 Treatment of Household Drinking Water by Seroprotection status
* 
 CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
No treatment 122 (85.9) 116 (81.7) 
Boiling 17 (12) 21 (14.8) 
Household 
water 
Treatment 
3 (2.1) 5 (3.5) 
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Table 6.22 Time taken to the Water Source by Seroprotection status

 
TIME  
(mins) 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
0 50 (35) 51 (36) 
2 42 (30) 54 (38) 
5 32 (23) 21 (15) 
10-15 13 (9) 13 (9) 
>15 5 (4) 3 (2) 
 
6.1.9. OPERATIONAL FACTORS OF THE STUDY POPULATION 
Two questions were asked about the village health nurse, firstly if they knew her 
and secondly if they were able to name her.  This was seen as a proxy for access to 
the health system and / or social inclusion. Majority of the cases (77.5%) and 
controls (83.8%) knew the VHN and 55.6% of the cases and 65.5% of the controls 
were able to name the VHN as seen in Table 6.23. There was some evidence to 
show an association with being a case and familiarity with naming the village 
health nurse (p= 0.089).  
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Table 6.23 Familiarity with the Village Health Nurse by Seroprotection Status

 
 
 
 
 
 
 
 
6.2. RISK FACTOR ANALYSIS 
Various risk factors were analyzed to assess the association with being a case. 
Results are presented under separate sections as demographic factors, parental 
related factors, birth related factors, breast feeding related factors, anthropometric 
factors, water and sanitation factors, and operational factors. 
 
6.2.1. UNIVARIABLE ANALYSIS: 
PER DOSE PROTECTION- The odds ratio of being a case with every increase 
in a dose was calculated to be 0.74 (95% C.I.: 0.59 – 0.93), suggesting a decrease 
in the odds of being a case with every additional dose. Assuming that the odds 
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YES/NO 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
Know 
 VHN 
YES 110 (77.5) 119 (83.8) 
NO 32 (22.5) 23 (16.2) 
Named  
VHN 
YES 79 (55.6) 93 (65.5) 
NO 63 (44.4) 49 (34.5) 
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ratio will be close to the risk ratio, the per dose protection was calculated as 1-
OR= 26% (95% C.I.:7% - 41%).  Figure 6.5 depicts the possible vaccine efficacies 
with every additional dose.  This is calculated based on the formula VE2= VE1 + 
(VE1 (100-VE1),   VE3= VE2 + ( VE1 (100-VE2))(89), where VE1,2,n denotes 
vaccine efficacy after dose 1, 2,n.  
 
 
 
Figure 6.7 Vaccine Efficacy versus No. of Doses 
 
DEMOGRAPHIC RISK FACTORS 
Gender, area of residence, type of house, religion, caste and SES were categorized 
and analysed for associations with lack of seroprotection.  None of the variables 
amongst demographic related risk factors showed any consistent association with 
being a case  
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Table 6.24 The effect of demographic factors on the Lack of Seroprotection

 
VARIABLE 
CASES 
N=142 
n (%) 
CONTROLS 
N = 142 
n (%) 
OR (95% C.I.) P – values 
Gender 
Male 71 (50) 79 (56) (Ref)  
Female 71 (50) 63 (44) 1.25 (0.79 - 2.00) 0.342 
Area of Residence 
Rural 62 (43.7) 57 (40) (Ref)  
Urban 80 (56.3) 85 (60) 1.16 (0.72 - 1.85) 0.548 
Type of House 
Pucca 105 (73.9) 96 (67.6) (Ref)  
Kutcha/Mixed 37 (26.1) 46 (32.4) 0.74 (0.44 – 1.23) 0.24 
Religion 
Others 118 (83.1) 119 (83.8) (Ref.)  
Muslim 24 (16.9) 23 (16.2) 1.05 (0.56 - 1.97) 0.873 
SES (Kuppuswamy Scale)  N=141                  N=142   
Middle/Upper 97 (68.8) 98 (69) (Ref.)  
Lower upper 44 (31.2) 44 (31) 1.01 (0.61 – 1.67) 0.968 
Caste                                N = 142                 N =140 
OC/BC/MBC 94 (66.2) 93 (66.4) (Ref.)  
SC 48 (33.8) 47 (33.6) 1.01 (0.62 -1.66) 0.967 
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The odds ratios were for female 1.25 (95% C.I.:0.79 - 2.00), urban 1.16 (95% 
C.I.:0.72 - 1.85), Kutcha/mixed 0.74 (95% C.I.:0.44 – 1.23), Muslim 1.05 (95% 
C.I.: 0.56 - 1.97), lower upper SES (Kuppuswamy group) 1.05 (95% C.I.:0.56 - 
1.97) and being in the Schedule caste 1.01 (95% C.I.: 0.62 -1.66). 
PARENTAL RELATED RISK FACTORS 
Amongst the parental related risk factors, the decrease in the odds of being a case 
per additional of year of mother’s education was  .92 with a 95% confidence 
interval of 0.86-0.99 as seen in Table 6.26.   For all other factors, there was little 
statistical evidence for an association. 
Table 6.25 The effect of parental factors on Lack of Seroprotection

 
VARIABLE 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
OR  
(95%C.I.) 
P – value 
Mother’s Education 
9
th
  & above 83 (58.4) 97 (68.3) (Ref)  
 None – 8th std 59 (41.6) 45 (31.7) 1.53 (0.94 -  2.49) 0.085 
Mother’s Occupation 
Housewife 116 (81.7) 125 (88) (Ref.)  
Working 26 (18.3) 17 (12) 1.65 (0.85 – 3.19) 0.139 
Father’s Occupation      N=141                 N=142 
Others 95 (67.4) 98 (69) (Ref.)  
Unskilled 46 (32.6) 44 (31) 1.08 (0.65 – 1.78) 0.767 
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Table 6.26 The effect of Parental Education (in years) on Lack of Seroprotection*  
 Coefficient OR (95% C.I.) P value 
Mother’s Education 
(total  yrs) 
-.0791721 
0.92 
(0.86- 0.99) 
0.034 
Father’s Education  
(total  years) 
-.0008674 
1 
(0.96 - 1.04) 
0.963 
 
BIRTH RELATED RISK FACTORS 
In the birth related risk factors, all variables including place of birth and birth 
weight and the presence of other siblings showed no association as seen in table 
6.33 and 6.34. The odds of a private health facilty birth as compared to 
government health facility on lack of seroprotection was 0.97 with the confidence 
interval crossing 1. Similarly with low birth weight and having more than one 
sibling as a risk factor for having lack of seroprotection was 0.83 and 1.2, with a 
95% C.I. crossing 1. 
Table 6.27 The effect of Birth related factors on Lack of Seroprotection

 
VARIABLE 
CASES 
N=142 
n (%) 
CONTROLS 
N=142 
n (%) 
OR (95% C.I.) P - values 
Birth – at Private 
Health Facility  
45 (31.7) 46 (32.4) 0.97(0.59 – 1.59) 0.899 
Low Birth weight 17 (12) 20 (14) 0.83 (0.41 – 1.66) 0.597 
Having  ≥1 
Sibling  
74 (52.1) 67 (47.2) 1.2 (0.76 – 1.94) 0.406 
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BREAST FEEDING RELATED RISK FACTORS 
In the breast feeding related risk factors, few of the variables showed any 
consistent association with being a case, including duration of exclusively breast 
feeding and initiation of water. There was however a trend towards introduction of 
complementary food after 4 months.  The odds of being a case increased by a 
factor of 2 with a 95% C.I.: 0.97 -1.67, when complementary feeds were given 
before 4 months. 
Table 6.28 The effect of Feeding practices on Lack of Seroprotection

 
VARIABLE 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
OR 
(95% C.I.) 
P - 
value 
Breast Feeding 
≥  6 months 26 (18.3) 24 (16.9) (Ref.) 
0.755 
0 - 6 months 116 (81.7) 118 (83.1) 0.91 (0.49 – 1.67) 
Complementary Feeds 
≥4  months 122 (85.9) 132 (93) (Ref.) 
0.058 
0-4  months 20 (14.0) 10 (7) 2.16 (0.97 - 4.81) 
Initiation of Water in Diet 
≥4  months 117 (82.4) 118 (83.1) (Ref.) 
0.875 
0-4  months 25 (17.6) 24 (16.9) 1.05 (0.57 – 1.94) 
 
Colostrum given 141 (99.3) 137 (96.5) 5.15 (0.59 - 44.62) 0.137 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
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ANTHROPOMETRIC MEASUREMENT RELATED RISK FACTORS: 
Amongst the anthropometric variables, there was some trend that each additional 
z-score of height-for-age decreased the odds of being a case (by about 18%), but 
the confidence interval just crossed the point of equivalence. To a lesser extend 
this trend was also observed for weight-for-age z scores. However, using 
established cut off points of these anthropometric measures (stunting, 
underweight, wasting) did not result in clinically relevant associations.  
 
Table 6.29 The effect of Anthropometric related factors on Lack of Seroprotection

 
VARIABLE ODDS RATIO 95% CONFIDENCE INTERVAL 
WHZ 1.02 0.80 1.30 
HAZ 0.82 0.65 1.04 
WAZ 0.89 0.68 1.15 
 
 
Similarly, there was no effect of stunting, wasting or being underweight on lack of 
seroprotection as seen in Table 6.30.  The O.R. were 0.85 (95% C.I.:0.49 – 1.48) 
for stunting, 0.87 (95% C.I.: 0.48 – 1.57) for wasting and 1.44 (95% C.I.:0.68 – 
3.07) for being underweight. 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
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Table 6.30 The effect of Stunting,Underweight and Wasting on Lack of 
Seroprotection

 
VARIABLE 
CASES 
n (%) 
CONTROLS 
n (%) 
OR (95% C.I.) P – value 
Stunting                         N =141              N = 141 
No 110 (78) 106 (75.2) (Ref.)  
Yes 31 (22) 35 (24.8) 0.85 (0.49 – 1.48) 0.574 
Underweight                 N=141              N= 141 
No 123 (87.2) 128 (90.8) (Ref.)  
Yes 18 (12.8) 13 (9.2) 1.44 (0.68 – 3.07) 0.343 
Wasting                            N=142              N=142 
No 116 (81.7) 113 (79.6) (Ref.)  
Yes 26 (18.3) 29 (20.4) 0.87 (0.48 – 1.57) 0.652 
 
WATER & SANITATION RELATED RISK FACTORS: 
In the water and sanitation related factors, none of the variables including sanitary 
practices, water source and treatment of water showed a clear association. There 
was however, some evidence that feeding treated water to the child at the time of 
initiating water feeding decreases the odds of lack of seroprotection.  
The odd ratio was 1.53, with the 95% confidence interval 0.92 – 2.54. 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
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Table 6.31 The effect of Water and Sanitation related factors on Lack of 
Seroprotection

 
VARIABLE 
CASES 
(N=142) 
n (%) 
CONTROLS 
(N=142) 
n (%) 
OR 
 (95% C.I.) 
P value 
Sanitary Practices 
Toilet 71 (50) 75 (53.8) (Ref.)  
Open Defecation 71 (50) 67 (47.2) 1.12 (0.70 – 1.78) 0.635 
Household Drinking Water Source  
Piped/Tap 114 (80.3) 115 (81.0) (Ref.)  
Others 28 (19.7) 27 (19.0) 1.05 (0.58 – 1.88) 0.881 
Household Drinking Water Treatment 
Yes 20 (14.1) 26 (18.3) (Ref.)  
No 122 (85.9) 116 (81.7) 1.37 (0.72 – 2.58) 0.335 
Feeding treated water to child – ( at time of initiating water) 
 
Yes 37 (30.7) 50 ( 35.2) (Ref)  
No 104 (73.8) 92 (64.8) 1.53 (0.92 – 2.54) 0.103 
 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
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OPERATIONAL RELATED RISK FACTORS 
Operational factors were studied, looking particularly at the distance to the health 
centre in terms of time taken to reach the centre, adjusting for the number of doses.  
In linear regression it was found that there was no relation with time taken to the 
vaccination centre and number of doses. Coefficient was -0.0036 (95% C.I.:-
0.0083 – 0.0011), with a p value of 0.13 and R squared = 0.008, suggesting a lack 
of an association. 
Knowing the village health nurse (VHN) and being able to name the VHN was 
also looked at as a proxy marker of the link to the health system.  Not able to name 
the VHN was found to increase the odds of being a case by 1.51 with the 
confidence interval just crossing 1 (0.94 – 2.44). 
 
Table 6.32 The effect of not being able to name the VHN on Lack of Seroprotection

 
VARIABLE 
CASES 
N=142 
n (%) 
CONTROLS 
N=142 
n (%) 
OR (95% C.I.) P value 
Not able to name 
VHN  
63 (44.4) 49 (34.5) 1.51 (0.94 – 2.44) 0.090 
 
 
                                              

 CASE - Children who are not seroprotected against type 3 poliovirus 
 CONTROL- Children who are seroprotected against type 3 poliovirus 
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6.2.2. MULTIVARIABLE ANALYSIS: 
A multivariable analysis was done building a complete model including all 
variables with p≤0.1 in univariable analysis (gender and SES were included for 
completeness despite p>0.1), as shown in Table 6.33. The following variables 
were included: mother’s occupation, mother’s education, giving colostrum, 
treatment of water at time of initiating drinking water for the child, height for age 
z score, not naming the village health nurse, age in months and total number of 
doses.  Here again age and total number of doses were chosen as potential 
confounder to be adjusted for as these showed strong associations with vaccine 
failure (= being a case). Age of weaning was dichotomized into 0-4 months and 4 
as added into the model.  
Giving colostrum became a significant variable after adjusting for all the other 
variables, with an odds ratio of 10.35 (95% C.I.: (1.03 – 104.40). Further, there 
was evidence that a working mother, inability to name the village health nurse 
increased the odds of lack of seroprotection. There was also some evidence that 
early weaning roughly doubled the odds of lack of seroprotection. 
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Table 6.33 Joint effects of risk factors on lack of seroprotection adjusted in a 
multivariable logistic model 
 
Unadjusted 
OR 
(95% C.I.) 
Adjusted 
OR 
(95% C.I.) 
P value 
Female 
1.25 
 
(0.79 - 2.00) 
1.31 
 
( 0.78 – 2.18 ) 
0.293 
Mother’s 
Education: (in 
yrs) 
0.92 
 
(0.86- 0.99) 
0.91 
 
( 0.84 – 0.99 ) 
0.034* 
Working mother 
1.65 
 
(0.85 – 3.19) 
2.11 
 
( 1.01- 4.4) 
0.047* 
SES 
(Lower – upper) 
 
1.01 
 
(0.61 – 1.67) 
0.78 
 
(0.44 – 1.38) 
0.402 
Colostrum given 
5.15 
 
( 0.59 – 44.62 ) 
11.77 
 
( 1.21 – 114.89 ) 
0.034* 
Weaning 
(<4months) 
2.16 
 
(0.97 - 4.81) 
2.2 
 
( 0. 94 – 5.15 ) 
0.068 
Not feeding 
treated water to 
child 
1.53 
 
(0.92 – 2.54) 
1.39 
 
( 0.80 – 2.44 ) 
0.244 
Height for Age Z 
scores 
(HAZ) 
0.82 
 
( 0.65 – 1.04 ) 
0.85 
 
( 0.66 – 1.11 ) 
0.234 
Not Naming VHN 
1.51 
 
(0.94 – 2.44) 
1.70 
 
( 1.00 – 2.88 ) 
0.048* 
Total Doses 
0.74 
 
( 0.59 – 0.93 ) 
0.81 
 
( 0.61 – 1.07) 
0.134 
Age 
(in months) 
0.84 
 
( 0.76 – 0.93 ) 
0.83 
 
( 0.73 – 0.95 ) 
0.005* 
*statistically significant 
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7.  DISCUSSION 
This thesis explored risk factors of poor immune response to OPV in a part-urban 
part rural low income population in a southern Indian state. The risk factors 
studied can be broadly classified as biological (e.g. nutritional status, age of 
weaning, feeding of colostrums), socio-economic (e.g. mothers education and 
occupation) and operational (e.g. time to reach institution in which OPV was 
given and familiarity with the VHN). The results of this thesis suggest that some 
of the explored biological (and therefore fairly proximal) potential risk factors, 
such as feeding colostrum, possibly low height-for-age z-score and early weaning 
were associated with vaccine failure. Further, there were trends towards several 
socio-economic factors such as maternal education, occupation and being able to 
name the village health nurse (possibly a proxy for access to the health system 
and / or social inclusion) being associated with vaccine failure. No evidence was 
found that other operational factors influenced vaccine efficacy. 
Biological factors such as breastfeeding have shown to affect immune response 
(49), with a marked reduction to type 3 (54).  However,  other studies have shown 
an increase in OPV titres with additional months of exclusive breastfeeding (46).  
It has also been suggested that maternal antibodies reduce the efficacy of the first 
dose of OPV (72),  which is later on mitigated by additional doses of OPV (72). 
Evidence suggests that exclusively breastfed children have higher anti polio IgA 
responses (46, 51).  This thesis supports this idea, as those given colostrum were 
74 
 
found to have an increased odds of vaccine failure and those with an early period 
of weaning were found to also have an increased odds of vaccine failure. 
Introduction of complementary food before 4 months increased the odds of being a 
case by 2.2 times with 95% CI just crossing 1 (0.94—5.15). This result makes the 
case for breastfed children to be more protected after OPV. 
Being female increased the odds of vaccine failure by 25% however the 
confidence interval was wide and crossed 1 (95% C.I.: 0.79 – 2.00).  The literature 
with respect to gender as a biological factor for vaccine failure is equivocal. The 
evidence with respect to possible associations between gender and vaccine failure 
continues to be unresolved (50, 52). 
The height of a child is an indirect indicator of the past nutritional status (54). 
Studies done in north India found malnutrition to be associated with a lower 
seroprevalence of antibodies to type 3 (59).  Although a trend can be found in our 
study with height for age z scores, as it just crosses the point of equivalence, it 
makes nutrition an unresolved factor associated to vaccine failure. With every 
increase in height z-score the odds of vaccine failure decreased by 8%. The 
association found in this study was not strong, in line with the conflicting evidence 
from previous studies (54, 58-60). Therefore, poor nutritional status can explain 
only a small proportion of the frequent vaccine failure in poor settings. 
Diarrhea has been shown in literature to be associated with reduced 
immunogenicity to type 3 poliovirus by 15% (48) and other studies showing 18% 
(53). A study done at Dhaka found diarrhoea to be a significant risk factor in 
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children in the first months after birth(65), however this effect was not clear in the 
third or fourth dose of OPV to type 3 in a study done at Brazil (59). The difference 
in the immunogenicity at different ages suggests a link to maternal antibodies 
which may add to the decreased immunogenicity at an early age and ware of with 
time.  It also suggests that the child’s immune system’s capacity to mount a 
response improves with age.  
Diarrhoea during OPV dose was a rare event in our study. As this question 
requires the mother to remember an event that might have occurred more than 6 
months ago, it could be that this information is not clear enough to find an 
association that is seen in many previous studies (40, 65). 
Some socioeconomic factors such as education and factors related to water and 
sanitation may affect immunogenicity (67, 68), and this was confirmed in this 
study especially with respect to mothers’ education level. The causal pathway 
from maternal education to vaccine failure is likely to be highly complex, possibly 
involving issues of hygiene, nutrition, wealth and water/sanitation. 
Our study found with every increase in the mother’s education (in years , the odds 
of being a case decreased by 8%.  When education was dichotomized into no 
education to secondary and high school and above education, the odds of being 
seronegative increased by 53% in those with a lower education with a 95% C.I. 
crossing 1, however  suggesting a possible association with vaccine failure.  
However, one can  say maternal education continues to rightly be a driving force 
in the prevention of many public health issues related to the child.  
76 
 
 
In the water and sanitation related factors, none of the variables including sanitary 
practices, water source and treatment of water didn’t show any association. There 
appeared to be a trend with not treating water given to children at the time of 
initiation of water, with the odds of vaccine failure increases by 53% and a 
confidence interval just crossing 1 (0.92 – 2.54). However, this may be partially 
due to confounding by socio-economic factors and mothers education.  
Naming the VHN can be seen as a proxy marker of accessibility to the delivery 
system and possibly social inclusion, indicating operational factors might be 
associated with vaccine failure. This study found some evidence to show an 
association with unfamiliarity with the village health nurse and being a case.  
Similar to maternal education the causal link between able to name the village 
health nurse and seroconversion is likely to be complex, and possibly subject to 
confounding. 
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8.  LIMITATIONS 
As evidenced by the fact that even some of the large effect sizes had confidence 
intervals crossing 1, the power to detect associations was still limited. A larger 
sample size would have been desirable. 
The calculation of the per dose vaccine efficacy is limited by the underlying 
assumptions: first the calculation assumes a linear association between number of 
doses and seroconversion. Very few children in this study had fewer than 3 doses. 
A linear trend at these doses can therefore not be readily assumed. Above 2 doses, 
the effect however appeared linear. Second, the calculations assume that the odds 
ratio approximates the risk ratio which requires the rare disease assumption where 
odds ratio and risk ratio can be assumed to be similar.  
Further limitations relate to the data quality. The vaccination history was recorded 
by the mothers’ report and confirmed by vaccination card where available. The 
mothers’ reporting was often unreliable as some of the mothers did not recall what 
vaccine had been given when. The vaccination cards were at times incomplete, 
and there were uncertainties whether vaccines were given or not (17%). However, 
combining data from verbal reports and vaccination cards should in the vast 
majority of cases provide us with reasonably accurate data on the number and 
approximate timing of OPV doses given. This is all the more the case as OPV as 
the only oral vaccine in the schedule and in contrast to other vaccines therefore 
had a good chance of being uniquely recognizable by mothers.  
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A further limitation relates to the observational nature of the study. Confounding is 
a common issue in these studies. Factors non-causally associated with being a case 
and with being exposed may exaggerate or dilute odds ratios especially in 
univariable analysis. For example, the association between not treating water 
given to children (OR 1,53) may be partially be due to confounding by socio-
economic factors and mothers education. Accordingly, the association was weaker 
in the adjusted analysis (OR 1,39). Residual confounding may explain some of the 
remaining association.     
The study was conducted in largely poor neighborhoods in Vellore town and 
villages throughout the district. Wealthier areas within Vellore were not included 
in the cohort from which children for this case control study were recruited. 
Therefore the results of this analysis are not necessarily representative for Vellore 
district as a whole, let alone for the state of Tamil Nadu or India. Nevertheless it is 
likely that similar associations may be found in other poor settings in India and 
elsewhere in South Asia or Africa, especially with respect to the biological factors 
studied.  
Case-control studies are at risk of selection bias, as it can be difficult to sample 
controls that come from the same source population as the cases. However, in this 
study selection bias is unlikely to have occurred as the study was nested in a larger 
cohort of children. The case/control status was determined based on serological 
data, after the children had already been recruited into the cohort. The source 
population of cases and control can therefore, for most practical considerations, be 
assumed to be identical. 
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9.  SUMMARY AND CONCLUSIONS 
The study showed associations between several biological factors and failure to 
mount an adequate immune response following OPV. Some of these risk factors 
are modifiable. In line with current public health policy, early weaning should be 
discouraged. The association between colostrum and vaccine failure appears to be 
high. However, giving colostrum is generally recommended to protect the child 
against common neonatal and infant infections such as pneumonia and diarrhea 
that carry a far higher risk of death than Polio. The finding from this and other 
studies of an increased risk of vaccine failure due to colostrums should therefore 
not change breastfeeding public health policy. Further public health measures to 
combat diarrhoeal diseases and malnutrition could contribute to improved immune 
response to OPV. In this context the socio-economic risk factors explored in this 
thesis are of interest as these can be regarded as upstream factors that modify the 
risk of ill health via many different pathways.  
Maternal education appears to contribute at least to some extent to the poor 
response to OPV in poor settings in India. These factors are also strongly 
associated with environmental enteropathy, a condition that recently has gained 
renewed interest in the research community because of its strong link with 
malnutrition and failure to thrive (67).  Environmental enteropathy may impair 
mucosal response to gastrointestinal infection including infection with OPV. It 
may partially explain the association between various socio-economic factors and 
lack of seroprotection following OPV. 
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Inequalities in wealth distribution, social inclusion, education and health care 
access continue to be the main factors for ill health in India even as the country 
on average becomes richer (90, 91). This thesis suggests that these mechanisms 
may extend to the immune response to oral polio vaccination.     
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10. RECOMMENDATIONS 
This study shows some evidence of early weaning as a risk factor for vaccine 
failure. Efforts to promote exclusive breastfeeding should therefore be supported 
also from the perspective of OPV efficacy.  Other risk factors identified in this 
study especially those related to socio-economic and educational factors are 
complex and unlikely to be easy targets for public health policy interventions. 
Until the question of social inequality is sustainably addressed, the policy of 
giving many repeat doses of OPV will continue to be required in low income 
settings across India in order to maintain sufficient levels of immunity to prevent 
re-emergency of polio.   
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12.  ANNEXURES 
Annexure 1 - STUDY PROFORMA 
NO QUESTION RESPONSE 
1 Rural/Urban 
Rural…………………..1 
Urban………………….2 
2 Village Name/ Ward Name 
Village (specify)____________ 
Ward (specify)_____________ 
3 
Interview Date  
 
 
I___.___I___.___I___.___I 
     DD          MM          YY 
4 
Who is the primary Caregiver 
 
Mother…………………………………….1 
Grandmother…………………………..2 
Others (specify)__________________..3 
5 Agree to participate: 
Yes……………………………………………………1 
No…………………………………………………….0 
 MATERNAL HISTORY  
6 Age 
 
                             (yrs) 
7 Education of Mother 
 
 
8 Occupation of Mother 
 
 
9 Number of children below 5 yrs of age 
 (excluding study child) 
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                               (no.) 
 BIRTH HISTORY  
10 Date of birth 
 
I___.___I___.___I___.___I 
     DD          MM          YY  
11 Place of Birth 
 
 
12 Gender 
Male………………………1 
Female………………….2 
13 Birthweight  
 
I______.______I kg 
14 Source Document (Birthweight) 
ANC Card ……………….1 
Immunization Card…2 
ANC Notebook………..3 
Others…………………….4 
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IMMUNIZATION HISTORY OF CHILD: 
15.CardAvailable:Y/N  
 
23.  Immunization (UIP) appropriate for age – other vaccines timely given   
Yes………….1                    
No…………..0 
24 .IMMUNIZATION HISTORY OF OTHER LIVING CHILDREN: (Routine Immunizations 
– 4   doses OPV) 
 
CHILD Complete : 
Y/ N 
Card present 
:Y/N 
1   
2   
3   
4   
 
Q.No. OPV DATE  
GIVEN 
(from 
CARD) 
AGE 
ADMINISTERED 
(MONTHS) 
(by history, when 
card absent) 
PLACE 
ADMINISTERED 
(write in words) 
 
 Specify       
LENGTH TIME 
TO REACH 
(mins) 
MODE  
 
16. 0       
17. 1       
18. 2       
19. 3       
 4       
 ADDITIONAL 
DOSES 
DATE 
GIVEN 
NID/ Non NID PLACE 
ADMINISTERED 
Documented(Y/N) If yes, 
Image 
no. 
20. 1       
21. 2       
22. 3       
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 BREASTFEEDING  
25. Did your child receive colostrum 
Yes……………………………………………………1 
No…………………………………………………….0 
26. 
When did the child start weaning? 
 
 
I________I (months) 
27. 
How long was the child exclusively breastfed 
(No water)? 
 
 
I________I (months) 
28. Was water included in this time 
Yes……………………………………………………1 
No…………………………………………………….0 
29. Which month did you start adding water? 
 
___________month 
30. Was the water treated 
Yes……………………………………………………1 
No…………………………………………………….0 
31. How was it treated? 
 
32. 
Is the child currently breastfed?  
 
Yes……………………………………………………1 
No…………………………………………………….0 
 
 
 
 MEDICAL  HISTORY  
33. 
Has the child had any hospitalisations other than 
immediately after birth?  
 
Yes……………………………………………………1                                  
No…………………………………………………….0 
34. Reason for hospitalization 
Specify_____________...........................1 
Not Applicable………………….………………0 
35. 
Did the child have diarrhea during the OPV 
doses? 
 
Yes……………………………………………………1 
No…………………………………………………….0 
36. Do you know the VHN in your area 
Yes…………………………………………………..1 
No……………………………………………………0 
37. What is her name 
Don’t know……………………………………..0 
 
Named:(specify)………………………………..1 
 SOCIOECONOMIC STATUS  
38. 
Type of House 
 
No house………………….0 
Pucca……………………….1 
Mixed……………………….2 
Kutcha………………………3 
 
39. Highest Education of Head of  Household 
 
 
40. Occupation of the Head of Household 
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41. 
Income (per month) 
 
 
42. Land Owned (wet) 
 
                       __________________ (acres) 
43. What is your Religion  
44. What is your Caste 
Specify:  
 
 WATER & SANITATION  
45. 
What is the main source of drinking water for 
your household? 
Piped/Tapincl 
municipality…………………….……….1 
Borewell…………………………..…….2 
Dugwell/Spring water…………….…….3 
Water tanker/cart…………………..…...4 
Bottled…………………………………...5 
Others 
(specify)_______________......................6 
46. Where is the water source located 
Inside house/compound….……………1 
Outside Compound…………………….2 
47. How long does it take reach your water source? 
 
___________________(mins) 
48. Treatment of water given to child 
No treatment……   …………………….1 
Boiling…………… …………….……….2 
Filter……………………………,……….3 
Boil & 
Filter…………………………….……….4 
Chemical…………………………………5 
Others (specify ………… .. ……………6 
49. 
Where do members of your household usually 
defecate? 
Toilet in the 
house/compound………………….….1 
Community 
toilet…………………………………..2 
Open Air/Field……………………….3 
50. Do you have a toilet in your house? 
Yes 
No 
51. Do you use this toilet  
Yes 
No 
 MEDICAL EXAMINATION  
52. Weight 
 
______ ( kg) 
53. Height/Length 
 
____       (cms) 
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Annexure 2 - Information Sheet - English 
You are being requested to participate in this research. The following information is 
provided to inform you about this research project. Please read this form carefully and 
please feel free to ask any questions you may have about the study or the information 
given below. You will be given an opportunity to ask questions, and your questions will 
be answered. Also, you will be given a copy of this information sheet. 
Your participation in this research study is voluntary.  
 
Purpose of this Research: 
Although children are given oral polio vaccine to fight against polio, there are some 
children who don’t develop protection to this virus. Many differences have been noted 
between those who develop immunity and those who don’t.  We have come to study 
risk factors and hope to understand better why some don’t develop protection while 
others do. 
 
If you take part, what will you have to do? 
If you agree, we will ask you a few questions regarding your child’s immunizations and 
other questions regarding the birth, breastfeeding and do a quick measurement of the 
child’s height and weight.  
 
Are there any risks involved? 
Participation in this study is not expected to present any risk or hazard to you or your 
child.  
 
Can you withdraw from this study after it starts? 
You may remember that your decision to take part is completely up to you. You can 
decide to stop being part of this study at any time. Dropping out of the study will not 
pose any disadvantages for you or your baby.   
 
Will you have to pay to participate in this study? 
No, there are no costs involved in participating in this study. 
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Will your personal details be kept confidential? 
All information you give us will be kept confidential, and not be shared with the 
government or any other organization.  However, your information may be reviewed by 
people associated with the study, without your additional permission, should you 
decide to participate in this study. 
 
If you have any further questions,  please ask 
Dr. Carol (telephone number:  04162284305 email: 
caroldevamani@cmcvellore.ac.in) 
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Annexure 3 - Informed Consent Form - English 
 
Study Title:Risk Factors for lack of seroprotection against type 3 OPV 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my child’s participation in the study is voluntary and that I 
amfree to withdraw at any time, without giving any reason, without medical care or 
legal rights being affected. [  ] 
 
(iii)  I understand that mine or my child’s identity will not be revealed in any 
information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s).[  ] 
 
(v)  I agree for my child to take part in the above study.[  ] 
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Signature (or Thumb impression) of the parent/Legally Acceptable  
 
Date: _____/_____/______ 
 
 
Signatory’s Name: _________________________________Signature:  
 
Or 
 
 
 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
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Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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Annexure 4 - Information Sheet - Tamil 
  
101 
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Annexure 5 - Informed Consent Form  Tamil 
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104 
 
Annexure 6 – Institutional Review Board Approval  
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